vs
Ensysce Biosciences, Inc.（ENSC）与波士顿科学（MLSS）财务数据对比。点击上方公司名可切换其他公司
波士顿科学的季度营收约是Ensysce Biosciences, Inc.的1.1倍（$2.1M vs $1.9M），波士顿科学净利率更高（-53.0% vs -147.0%，领先94.1%），Ensysce Biosciences, Inc.同比增速更快（44.4% vs 2.2%），过去两年Ensysce Biosciences, Inc.的营收复合增速更高（107.9% vs -4.3%）
Ensysce Biosciences是一家临床阶段生物技术公司，专注于开发疼痛管理和肿瘤适应症领域的创新前药疗法，其专有平台可降低阿片类药物滥用风险并提升治疗有效性，面向全球医疗医药市场，重点解决未被满足的临床需求。
波士顿科学公司是源自美国的跨国生物医疗企业，专业研发生产介入医疗领域医疗器械，产品覆盖介入放射学、介入心脏病学、外周介入治疗、神经调控、神经血管介入、电生理、心脏外科、血管外科、内镜、肿瘤学、泌尿与妇科等多个领域。
ENSC vs MLSS — 直观对比
营收规模更大
MLSS
是对方的1.1倍
$1.9M
营收增速更快
ENSC
高出42.2%
2.2%
净利率更高
MLSS
高出94.1%
-147.0%
两年增速更快
ENSC
近两年复合增速
-4.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.9M | $2.1M |
| 净利润 | $-2.8M | $-1.1M |
| 毛利率 | — | 73.0% |
| 营业利润率 | -147.8% | -52.5% |
| 净利率 | -147.0% | -53.0% |
| 营收同比 | 44.4% | 2.2% |
| 净利润同比 | 22.3% | 46.4% |
| 每股收益（稀释后） | $-0.51 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENSCMLSS
| Q4 25 | $1.9M | $2.1M | ||
| Q3 25 | $493.1K | $2.4M | ||
| Q2 25 | $1.4M | $2.3M | ||
| Q1 25 | $1.3M | $2.2M | ||
| Q4 24 | $1.3M | $2.0M | ||
| Q3 24 | $3.4M | $2.5M | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $2.2M |
净利润ENSCMLSS
| Q4 25 | $-2.8M | $-1.1M | ||
| Q3 25 | $-3.7M | $-1.2M | ||
| Q2 25 | $-1.7M | $-1.5M | ||
| Q1 25 | $-1.9M | $-2.0M | ||
| Q4 24 | $-3.6M | $-2.0M | ||
| Q3 24 | $661.8K | $-1.5M | ||
| Q2 24 | — | $223.6K | ||
| Q1 24 | — | $-1.4M |
毛利率ENSCMLSS
| Q4 25 | — | 73.0% | ||
| Q3 25 | — | 69.5% | ||
| Q2 25 | — | 69.6% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | 75.0% | ||
| Q3 24 | — | 73.0% | ||
| Q2 24 | — | 76.1% | ||
| Q1 24 | — | 74.5% |
营业利润率ENSCMLSS
| Q4 25 | -147.8% | -52.5% | ||
| Q3 25 | -758.7% | -48.1% | ||
| Q2 25 | -127.6% | -63.9% | ||
| Q1 25 | -149.1% | -89.5% | ||
| Q4 24 | -274.3% | -101.4% | ||
| Q3 24 | 18.9% | -58.4% | ||
| Q2 24 | — | -96.0% | ||
| Q1 24 | — | -65.1% |
净利率ENSCMLSS
| Q4 25 | -147.0% | -53.0% | ||
| Q3 25 | -756.3% | -48.9% | ||
| Q2 25 | -126.4% | -63.8% | ||
| Q1 25 | -147.4% | -89.3% | ||
| Q4 24 | -273.4% | -101.1% | ||
| Q3 24 | 19.4% | -58.1% | ||
| Q2 24 | — | 12.1% | ||
| Q1 24 | — | -64.1% |
每股收益（稀释后）ENSCMLSS
| Q4 25 | $-0.51 | — | ||
| Q3 25 | $-1.29 | $-0.01 | ||
| Q2 25 | $-0.79 | — | ||
| Q1 25 | $-1.39 | — | ||
| Q4 24 | $-0.89 | — | ||
| Q3 24 | $1.00 | $-0.02 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.3M | $1.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.2M | $2.8M |
| 总资产 | $7.5M | $7.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ENSCMLSS
| Q4 25 | $4.3M | $1.1M | ||
| Q3 25 | $1.7M | $1.3M | ||
| Q2 25 | $2.2M | $1.3M | ||
| Q1 25 | $3.1M | $2.2M | ||
| Q4 24 | $3.5M | $3.3M | ||
| Q3 24 | $4.2M | $4.8M | ||
| Q2 24 | — | $5.8M | ||
| Q1 24 | — | $5.0M |
股东权益ENSCMLSS
| Q4 25 | $3.2M | $2.8M | ||
| Q3 25 | $1.2M | $2.5M | ||
| Q2 25 | $3.4M | $3.3M | ||
| Q1 25 | $3.0M | $4.5M | ||
| Q4 24 | $3.7M | $5.8M | ||
| Q3 24 | $6.9M | $7.2M | ||
| Q2 24 | — | $8.0M | ||
| Q1 24 | — | $7.5M |
总资产ENSCMLSS
| Q4 25 | $7.5M | $7.8M | ||
| Q3 25 | $3.2M | $8.5M | ||
| Q2 25 | $5.6M | $8.1M | ||
| Q1 25 | $4.6M | $9.1M | ||
| Q4 24 | $5.6M | $9.8M | ||
| Q3 24 | $9.4M | $11.2M | ||
| Q2 24 | — | $12.0M | ||
| Q1 24 | — | $11.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.5M | $-226.1K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ENSCMLSS
| Q4 25 | $-1.5M | $-226.1K | ||
| Q3 25 | $-1.9M | $81.8K | ||
| Q2 25 | $-2.7M | $-1.8M | ||
| Q1 25 | $-1.7M | $-1.0M | ||
| Q4 24 | $-764.1K | $-1.5M | ||
| Q3 24 | $-1.0M | $-973.9K | ||
| Q2 24 | — | $783.7K | ||
| Q1 24 | — | $-1.2M |
现金转化率ENSCMLSS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.54× | — | ||
| Q2 24 | — | 3.50× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
